Several major Wall Street analysts updated their ratings and price targets for Ionis Pharmaceuticals. While all maintained 'buy' ratings, most significantly lowered their price targets, indicating a revised, less optimistic valuation for the company.
On November 14, 2026, multiple prominent analysts updated their research on Ionis Pharmaceuticals. While all maintained their 'buy' ratings, Morgan Stanley, TD Cowen, and BMO Capital significantly reduced their price targets, suggesting a downward revision in their valuation outlook for IONS. Barclays and Wells Fargo maintained their targets, offering some stability. This collective action indicates a shift in analyst sentiment, potentially due to new data, market conditions, or revised growth expectations for Ionis's pipeline or existing drugs. For traders, this could signal short-term downward pressure on the stock as the market digests these lower valuations, despite the maintained 'buy' ratings. The key risk is that these lowered targets could lead to a re-rating of the stock by the broader market, impacting investor confidence.